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ABSTRACT
The paramyxovirus replication machinery comprises the viral large (L) and phospho-(P) proteins
in addition to the nucleocapsid (N) protein that encapsidates the single stranded RNA genome.
Common to paramyxovirus N proteins is a C-terminal tail (Ntail), which contributes to docking
of the polymerase complex to the genome through defined interaction domains. The central Ntail
section is structurally disordered and thought to provide spatial flexibility required for productive
interaction of the polymerase with the encapsidated viral genome, but its mechanistic role and
relevance for successful virus replication is untested. Focusing initially on members of the
morbillivirus genus, a series of Measles virus (MeV) and Canine distemper virus (CDV) N
proteins were generated with internal deletions in the unstructured tail section. N proteins with

large tail truncations remained bioactive in mono- and polycistronic minireplicon assays and
supported efficient replication of recombinant viruses. Bioactivity of Ntail mutants extended to
N proteins derived from highly pathogenic Nipah virus (NiV), a member of the henipavirus
genus. To probe an effect of Ntail truncations on viral pathogenesis, recombinant CDVs were
analyzed in a lethal CDV/ferret model of morbillivirus disease. The recombinant viruses
displayed different stages of attenuation ranging from ameliorated clinical symptoms to complete
survival of infected animals, depending on the molecular nature of the Ntail truncation.
Reinfection of surviving animals with pathogenic CDV revealed robust protection against a
lethal challenge. The highly attenuated was genetically stable after extensive ex vivo passaging
and recovery from infected animals. Mechanistically, gradual viral attenuation coincided with
stepwise-altered viral transcriptase activity in infected cells. These results identify the central
Ntail section as a determinant for viral pathogenesis and establish a novel platform to engineer
gradual virus attenuation for next-generation paramyxovirus vaccine design.
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1
1.1

INTRODUCTION

Paramyxoviridae family
Mononegavirales (non-segmented, negative sense RNA viruses) comprises eight major

families, which include human and animal pathogens: 1) Bornaviridae (for example- Borna
disease virus (BDV)), 2) Filoviridae (for example-Ebola virus, Marburg virus), 3)
Paramyxoviridae (for example- Measles virus (MeV), Canine distemper virus (CDV), Mumps
virus (MuV), Henipaviruses (Hendra virus (HeV) and Nipah virus (NiV)), 4) Pneumoviridae (for
example- human respiratory syncytial virus (RSV)), 5) Rhabdoviridae (for example- rabies virus,
vesicular stomatitis virus (VSV)), 6) Mymonaviridae (Sclerotimonavirus), 7) Nyamiviridae (for
example- Nyavirus), 8) Sunviridae (Sunshine virus). Paramyxoviridae family is further divided
into different genera including Rubulaviruses (for example- MuV), Respiroviruses,
Henipaviruses (for example- NiV), Morbilliviruses (for example- MeV and CDV), and
Avulaviruses, Aquaparamyxoviruses and Ferlaviruses (1)

Members of the Paramyxoviridae family are mostly pathogenic, contagious and infect a
variety of hosts through the respiratory route. Paramyxoviridae virions are generally
pleiomorphic in shape and 150-350nm in diameter. Paramyxoviruses infect cells through fusion
with the plasma membrane. They induce cell-cell fusion, thereby creating giant multinucleated
cells (syncytia) (2)

Paramyxoviridae genomes are similar in gene order and intergenic junctions separate the
genes. Some differences in these genomes are their different attachment proteins. Respiroviruses
and Rubulaviruses have hemagglutinin-neuraminidase [HN] attachment protein, while
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Morbilliviruses have hemagglutinin [H] and Henipaviruses have G as their attachment protein in
different genera of Paramyxoviridae subfamily. The envelope of the MeV virion contains two
glycoproteins: F or the fusion protein, which promotes fusion of the viral and host cell
membranes, and H-which is the viral attachment protein. The matrix protein (M protein) forms
an electron-dense layer underlying the viral bilayer. M regulates MeV RNA synthesis and
particle assembly by interacting with the nucleoprotein [N] as well as the lumenal tails of H and
F (2-4).

All members of paramyxoviridae share a common mechanism of RNA synthesis. Viral
RNA synthesis occurs in the cytoplasm and involves the N, phosphoprotein (P) and large protein
(L). The viral polymerase (RNA-dependent RNA-polymerase/RdRp) is a hetero-oligomer
composed of the L and P proteins. L performs all of the enzymatic activities while P acts as a cofactor. P chaperones newly synthesized N protein (N0) to the RNA template during replication
(5-7), binds L, and also interacts with the nucleocapsid/ribonucleoprotein (RNP) template to
mediate transcription and replication, respectively (8).

Polymerization initiation can be performed in different ways for different single stranded
RNA viruses. There are two kinds of different mechanisms: de novo and primer-dependent
initiation. In addition to MeV, VSV and RSV demonstrates de novo synthesis. In case of VSV
and RSV, the polymerase preloads with the first two and three nucleotides respectively (9, 10).
Some positive sense RNA viruses use a primer-dependent initiation mechanism, while a cap
snatching mechanism is used by Influenza. The endonuclease cleaves capped RNAs to generate
the primers that initiate viral RNA transcription (11), but in case of replication it uses a de novo

3

mechanism (12). The switch mechanism between transcription and replication is not fully
understood. For example, the RSV polymerase can initiate polymerization at either +1 or +3
position (13). It has also been proved that the regulation of transcription and replication also
depends on host proteins as shown with the leader region of MeV polymerase (14).
MeV P encodes two additional nonstructural proteins- the C and V proteins. Alternative
translation initiation or RNA editing, respectively, expresses these proteins. By inhibiting the
interferon signaling, C and V interfere with the innate host immune response (3, 4). The C
protein interferes with IFN induction via its regulatory role in viral RNA synthesis. Viral RNAs
accumulate in cells infected with MeV-(ΔC) virus, possibly stimulating host innate immune
responses (15, 16). V protein is formed by the insertion of a non-templated guanine nucleotide at
a precise location, called an “editing site,” which generates an mRNA which differs from that of
P with an altered ORF downstream of the editing site. Thus, due to this specific mechanism, the
N-terminal domain of P and V are identical, whereas their C-terminal domains are unique (17).
The V protein blocks the JAK–STAT signalling pathway by interacting with STAT1 and STAT2
(18).

Some members of the Paramyxoviridae family are responsible for pediatric morbidity
and mortality. Vaccines have been successful in providing protection from some
paramyxoviruses, such as MeV and MuV. MeV is one of the most readily transmitted
communicable diseases infecting children. There is an effective Measles-Mumps-Rubella
vaccine recommended by the World Health Organization (WHO). WHO recommends two doses
of the MMR vaccine- the primary dose is administered to children within 9-15 months of age and
the booster dose is given between 2-5 years of age. Exposure to either wild type or attenuated
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MeV in form of the MMR vaccine delivers a lifetime protection mediated by antibodies
delivered from memory B cells (19, 20). However, natural boosting is required to maintain
protection since antibodies induced by the vaccine wane over time.

The highly efficacious MMR vaccine has currently failed to eliminate MeV worldwide.
A herd immunity of 95% is required in order to prevent MeV endemic outbreaks (21) because
MeV typically reemerges first when vaccination coverage in a population drops (22). On the
other hand, a fraudulent article reports that the MMR vaccine is linked to the development of
autism in 1998 and this has led to many anti-vaccination campaigns (23). Although the research
has been proven flawed (24, 25), many parents are still scared to vaccinate their child.

Unfortunately, no vaccine exists for the newly emerging paramyxovirses like NiV (26),
despite major research efforts. The Hendra vaccine has been shown to be cross-protective
against NiV infection in the non-human primate model (27). A NiV-specific monoclonal
antibody has been shown to be protective in non-human primates (28). The efficacy of some
vaccines (such as CDV vaccine) still remains questionable (29). Thus, there is an urgent need
for the development of new and highly efficient strategies to prevent infections and provide
potent therapeutic treatment to treat many outbreaks that still occur.

1.2
1.2.1

Morbillivirus genus
Measles virus (MeV)
For many Morbilliviruses, the tropism and tissue distribution is found to be similar. There

are three main receptors used by MeV for attachment and cell entry. The first is CD46, a
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ubiquitously expressed receptor on all nucleated cells. Its physiological function is to protect the
cells from attack of invading pathogens by regulating complement activation and also regulates
innate and acquired immune responses. The vaccine and laboratory-adapted MeV strains use
CD46 for attachment and entry (30, 31). The second is the signaling lymphocyte activation
molecule (SLAM/CD150), expressed on immune cells like the activated T and B cells,
macrophages and mature dendritic cells (DC’s). SLAM functions by interacting with another
SLAM molecule on the adjacent cell and undergoes its tyrosine phosphorylation to produce Thelper cytokines: interleukin (IL)-4 and IL-13 (32, 33). The functions and distribution of SLAM
receptor proves the lymphotropic and immunosuppressive nature of MeV. The third receptor is
Nectin-4/PVRL4, which is expressed on epithelial cells located on the basolateral side of the
airway epithelium (34, 35). Other receptors that have been identified are DC-specific ICAM-3
grabbing non-integrin (DC-SIGN) and neuronal cell-specific Neurokinin-1 (NK-1) (36).

MeV is transmitted via the respiratory route and infects resident DC’s and alveolar
macrophages (AM’s) in the lungs. Infected DCs and AM’s transport MeV to the draining lymph
nodes where they infect the lymphocytes via the SLAM receptor. A transient fever at 3-6 days
post MeV infection coincides with primary viremia. The virus is largely lymphotropic and
spreads through lymphoid organs and tissues such as spleen or thymus as well as the liver, skin,
tonsils and respiratory mucosal surfaces. This causes the secondary viremia (37). High fever coincides with viremia and other symptoms such as cough, coryza, Kopliks’s spots occur 10-12
days post infection. The trademark maculopapular rash occurs later at around 14-15 days post
infection. This occurs because of the infiltration of cytokines into sites of MeV replication (38).
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Nectin-4/PVRL4 receptor is involved in MeV spread through virus infected immune cells
to the basolateral side of the airway epithelium. This finally results in virus shedding (39). A
large number of infected cells present in the respiratory tract cause the symptoms such as
coughing and sneezing and sometimes pneumonia. This allows the virus to undergo host-to-host
transmission, which contributes to MeV outbreaks (40).

MeV causes suppression of the adaptive immune response. Some studies show decreased
IL-12 and increased IL-4, IL-10 production that changes Th1 response to a prolonged Th2
response. The infection also causes T cell non-responsiveness due to virus-induced immaturity of
infected DC’s (41-45). MeV infection also suppresses the proliferation of lymphocytes (46). This
unresponsiveness can be caused by contact of lymphocytes with the viral glycoprotein on MeV
virions or MeV-infected cells, independently of virus replication in lymphocytes. It may also be
caused due to the H protein interaction with SLAM on lymphocytes (47). At the same time, MeV
induces strong immune responses that confer lifelong immunity (48). This contradiction is
known as the ‘measles paradox’. The lymphocyte numbers generally return to normal within a
week after the disappearance of MeV clinical symptoms, while the immune suppression extends
for several weeks to months. It is therefore believed that MeV immune suppression mainly
results from depletion of immune cell subsets, but this is in turn masked by the rapid
proliferation of MV-specific lymphocytes (49).

Additionally, MeV-induced autoimmune demyelination of neurons in the brain, known as
acute disseminated encephalomyelitis (ADEM), can occur within 2 weeks after the onset of
infection. Progressive measles inclusion body encephalitis (MIBE) can arise after the virus has
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cleared from the host (50, 51). Another fatal disease of the central nervous system (CNS) is the
subacute sclerosing panencephalitis (SSPE). SSPE can occur several years later after infection
and is caused by demyelination and presence of MeV in neuronal cells of the brain (52). As of
today, it is unclear how MeV infects neurons within the CNS (53) and circulating virus specific
antibodies alone fail to clear the virus.

1.2.2

Canine distemper virus (CDV)
CDV, another member of Morbillivirus genus, is a common cause of morbidity and

mortality in unvaccinated domestic or feral dogs. It also affects other carnivores such as cats,
lions, tigers, bears and is also very common in some endangered species and other aquatic and
terrestrial carnivores (54-60)
The use of SLAM receptor is common to the Morbillivirus genus. CDV uses dog SLAM
as its principal receptor for viral entry. Like MeV, CDV also spreads by aerosol and causes
primary and secondary viremia. CDV infection is also mainly lymphotropic. It causes clinical
symptoms such as fever, rash, conjunctivitis, pneumonitis, and neurological diseases. In the case
of CDV infection, acute encephalomyelitis is often observed. Also, symptoms like hyperceratosis
of footpads and epithelium of the nasal tract are very often observed. CDV shows the same
disease profile in ferrets as MeV causes in humans. Although, the live-attenuated CDV vaccines
are fully apathogenic in dogs, they can cause severe clinical distemper in sensitive species such
as black-footed ferrets or other carnivores (29).
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Animal models:
CDV disease is very severe and leads to 100% mortality in ferrets after intranasal
infection. Therefore, the lethal CDV-ferret animal model (29) is the most commonly used smallanimal model system for the members of the Morbillivirus genus. It is used as the surrogate
model as there is no other suitable animal model for MeV except the macaques, which are
inaccessible, expensive and do not show all the classic symptoms except mild rash and transient
lymphopenia (61, 62). Rodent models like mice expressing transgenic CD46 (63, 64) or cotton
rats (65) do not replicate the exact MeV pathogenesis and virulence.

1.3
1.3.1

Henipavirus genus
Nipah virus (NiV)
Henipaviruses have a broad species tropism including flying fox species, fruit bat species

which are the reservoirs for the viruses in this genus (66). NiV is a highly lethal zoonotic
paramyxovirus. The natural infection occurs in pigs and is amplified in them. The first outbreak
occurred in peninsular Malaysia in 1998. NiV first infected pig farmers working in contact
with pigs and this was the primary cause of the outbreak. Numerous cases of encephalitis
among pig farmers were reported. The pigs had been infected through consumption of
contaminated fruit from infected fruit bats (Pteropus spp.). Pig-human transmission occured
accidentally. Infection in humans is found to be severe (67-71) Subsequent deadlier outbreaks
occured in Bangladesh and India. Human-to-human transmission in home or hospital settings
has also been documented (72, 73) High case fatality rate by NiV infection emphasizes the
urgent need for prophylactic or therapeutic medical treatments.
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Ephrin-B2 or B3 is known to be the functional receptor for Henipavirus genus and is
found on arteries, arterioles and capillaries in various organs. The viruses attach to the receptor
and infect host cells using the attachment G and the fusion F proteins (74, 75). The common
symptoms include fever, headache, drowsiness, hypertension, and encephalitis. Atypical
pneumonia and acute severe respiratory syndrome is also common (17). No vaccines are
available to treat NiV infection and therefore, it is very important to develop a safe and
efficacious vaccine (76).

1.4

Replication machinery of Paramyxoviridae members
Negative-sense viruses (NSV) contain RNP complexes, which are formed when the

genomic as well as the antigenomic RNA are encapsidated by the viral N protein.
Paramyxoviruses forms a characteristic herringbone structure in EM images. RNP’s act as the
template for both transcription and replication. In addition, P and L proteins are also involved in
both transcription and replication, but the two processes are different (77).
PCT
PNT
1

PMD
230

304

XD
376

459

507

Figure 1: Schematic representation of MeV phosphoprotein (not drawn to scale)
having a N-terminal (PNT) and a C-terminal (PCT) including a tetramerization domain
(PMD) and a C-terminal RNP binding domain (P-XD).

MeV P protein consists of 400-600amino acids and its physiological oligomer is the
tetramer. It is very highly phosphorylated protein. P is the polymerase cofactor and links the L
polymerase to the RNP template. It comprises of L (polymerase) binding site and N binding site.
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The MeV P protein is comprised of an N-terminal (PNT) domain (1-230aa) and a C-terminal
(PCT) domain (231-507aa) as shown in figure 1. PNT chaperones newly synthesized N protein
(N0) to the RNA template during replication. PNT also holds N monomers in an open
conformation and prevents premature oligomerization (7). PCT includes a tetramerization
domain (PMD) and a C-terminal RNP binding domain (P-XD) that mediates high-affinity
interactions with the N protein (78-80).

MeV L protein is a 2200 AA (220 to 250 kDa) protein and its structural organization and
location of individual enzymatic activities are very well understood. The L protein contains all
enzymatic (capping, methylation, adenylation, RNA binding) activities associated with mRNA
synthesis and genome replication. The L protein is comprised of six domains- domain II
considered to be associated with RNA binding, domain III harbors the predicted catalytic center
for phosphodiester bond formation and domains V and VI postulated to mediate capping
functions (81-83).

Viral replication of Paramyxoviridae takes place in the host cell cytoplasm after viral
entry and uncoating of the genome into the cell. For both transcription and replication, the viral
polymerase complex initiates polymerization at the 3’ end of the RNP (84). N wraps around 6
nucleotides of RNA and follows the rule of six. These genomes are of negative polarity and thus
the viral RdRp transcribes into mRNA first, which gets capped and polyadenylated by the L
protein. 3’ and a 5’ noncoding leader and trailer regions, respectively, flank the coding regions of
the non-segmented genome. The viral polymerase promoter is present in the noncoding regions
and gene start/stop signals are in the intergenic junctions that separate each of the individual
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genes. For both transcription and replication, the viral polymerase complex exclusively initiates
polymerization at the 3’ end of the N encapsidated RNA (84). In the case of transcription, the
MeV RdRp complex scans and polymerizes along the template until it encounters the
polyadenylation signal to produce monocistronic N mRNA at position 55. The complex then reinitiates to transcribe the next gene. Some premature falling of the polymerase complex with
increase in template length occurs and creates a gradient of gene expression in which the genes
that are closer to the promoter are more abundant. The likelihood of premature detachment
increases with template length, resulting in lower mRNA levels of downstream genes, which
creates the transcription gradient. When enough N protein is produced to encapsidate the nascent
RNA, the RdRp complex switches from transcription to replication. In replication mode, the
MeV RdRp complex ignores the intergenic junctions in between genes. It produces a complete
plus polarity copy of the genome (antigenome), which is concurrently encapsidated by N (8).
The polymerase initiates antigenome production from the leader region. The RdRp complex does
not recognize any non-encapsidated RNA (85)

1.5

Nucleoprotein
N proteins from Paramyxoviridae members are approximately 500 or more amino acids

in length. Their function is to encapsidate the viral genomic RNA to form RNP. N does not bind
to any cellular RNA or viral mRNAs. Unassembled N interacts with P called the No-P complex
that involves the interaction between Ncore and PNT. This complex helps in guiding N to newly
synthesized genomic RNA prevents N from nonspecifically binding cellular RNA. However,
when used in heterologous systems, and in the absence of other viral proteins, N will bind
cellular RNAs and form structures that are similar to authentic viral RNP (86, 87).
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Figure 2: Cryo-EM structure of the MeV Ncore RNA nucleocapsid at near-atomic
resolution (From: Irina Gutsche et al. Science 2015;348:704-707)
(A) Schematic of MeV N (navy blue, NTD arm; blue, NTD; salmon, CTD; yellow, CTD arm).
The same color code (with RNA in green) is used for the rest of the figure. (B and C) Isosurface
representation of the cryo-EM 3D reconstruction of the helical nucleocapsid: (B) front view, (C)
cutaway view.

Recently, a 4.3Å resolution structure of the MeV helical nucleocapsid was solved
using cryo-electron microscopy. This structure clearly defined the interactions between MeV N
and the encapsidated RNA. The RNA thread winds around the MeV nucleocapsid: inside the
cavity between the N-terminal domain (NTD) of the N-core and the C-terminal domain (CTD) of
the N-core as shown in figure 2. A hinge region between NTD and CTD may allow for an openclosed transition during RNP formation (88).
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Figure 3: Schematic representation of Paramyxoviridae nucleoproteins (not drawn
to scale) having a conserved N-core and a flexible N-tail.

All paramyxoviridae N proteins have a conserved amino terminal domain, known as Ncore, and a flexible and poorly conserved, intrinsically disordered and is highly flexible Cterminal domain, known as N-tail (as shown in figure 3). MeV-N features a 400-residue aminoterminal RNA-binding core (N-core) and a 125-residue carboxy-terminal tail domain (N-tail).
The presence or absence of the N-tail affects the overall spatial organization of the RNP. It has
been demonstrated that complete removal of the N-tail by trypsin digestion leads to complete
loss of RdRp bioactivity. This is due to the decrease in the MeV N:RNA diameter and pitch that
causes extreme rigidity (89). Decrease in flexibility due to the decrease in the diameter may be
affecting the RdRp processivity and this may lead to the loss of RdRp bioactivity.

Some studies show that the N-tail is essential for RdRp-mediated transcription and
replication (90-93). There are conserved microdomains in N-tail (box 1-3) that are important for
MeV replication. Box 1 (401-420a.a) binds to an uncharacterized nucleoprotein receptor (NR)
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(94). Box 2 (488-499a.a), also known as the molecular recognition element i.e. MoRE interacts
with the X-domain (XD) in the C-terminal of the P protein (91). This interaction is thought to
stabilize the RNP template which is very important for allowing the polymerase complex to
progress along the template for transcription and replication of the virus (80). It is a reversible
phenomenon since the interaction has to be made and broken to allow the polymerase to progress
during transcription and replication unless P remains static and L moves (95). Box 3 (517525a.a) stabilizes the MoRE-XD interaction (80, 96, 97). Furthermore, box 3 is thought to
interact with the M protein (3) and with the heat shock proteins to facilitate efficient genome
replication and incorporation of the genome into nascent particles (3, 98, 99).

In a recent study, it was demonstrated that the MeV nucleocapsid protein tail domain is
dispensable for polymerase activity. The truncated N-tail mutant (N-Δ86) restored the
polymerase complex activity in a minigenome system. In order to test the bioactivity of the
central section of the N-tail region, a plasmid mutant was designed and the conserved N-tail
boxes were kept intact. This MeV N-tail mutant showed higher polymerase activity as compared
to its standard but the recombinant mutant virus was not replication competent. By qPCR
analysis, it was also shown that the presence of fully N-tail truncated mutant affected the stability
of RdRp binding to RNP’s and that the likelihood of abortive separation of RdRp from the RNP
template was increased in the absence of the N-tail MoRE domain. Thus, it was concluded that
the MoRE:P-XD interaction is required to prevent catastrophic premature polymerase
termination (80).

In another study, the placement of the MoRE near the MeV N-tail terminus was shown
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not to be important for virus replication and that MORE could be placed in the MeV conserved
N-core. It was also confirmed that MORE is not important for loading of RdRp onto and/or
RdRp progression along the RNP template (100). A regulatory role of the central section seems
to exist and to define that was the main objective of the following study.

Figure 4: Schematic representation of MORE-XD interaction in the presence of
Morbilliviral N-standard and a central section truncated mutant.
The main hypothesis of my Ph.D work was that the central section of the morbilliviral Ntail is not important for virus replication and would be responsible for a specific polymerase
regulatory role. This is shown in the figure 4, which shows that by truncating the central section
of the N-tail, the morbilliviral replication would not be affected.

In the subsequent chapters, a detailed overview of a minireplicon/ bioluminescent
reporter assay systems is given as they are very commonly used to study gene expression as well
as other cellular components and events that are involved in gene regulation.

Advantages: Such virus-free reporter assay systems have also been widely used for screening
antiviral drugs. Many compounds have been tested for potential antiviral activity using reporter
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assay systems (89). Various luciferase reporters are used for a high-throughput screening (HTS)
protocol design that can identify paramyxovirus-speciﬁc, orthomyxovirus-speciﬁc, or broadly
specific compounds in a single assay system (101). Furthermore, prior to rescuing a recombinant
virus from its full-length cDNA, a minireplicon reporter system is used to verify the validity of
the rescue protocol experimental process (102).

1.6

Monocistronic Minireplicon / Bioluminescent assays
Minireplicon/Bioluminescent assays depend on enzymes called luciferases. Luciferases

or luciferase enzymes are classified as oxidative enzymes found in several species that enable the
organisms that express them to eradiate bioluminescence. These enzymes emit a photon and in
turn allow the oxidation of luciferins to form oxyluciferin. There are many structurally diverse
luciferin substrates. Many bioluminescence-producing organisms are isolated in order to utilize
them for this assay, including luciferases from fireflies and various marine organisms such as the
sea pansy that belong to the families Lampyridae and Renillidae respectively (103, 104).

Figure 5: Schematic representation of a bioluminescent assay system driven by T7
promoter and T7 polymerase
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1.6.1

Minigenome construct
Minigenomes are smaller in length and easier to manipulate. They usually only carry a

single reporter gene open reading frame flanked by the leader and trailer as shown in figure 5
(105). Thus, the minigenome system is constructed to mimic viral gene expression in the same
way.

Promoters are found upstream of target genes for specific polymerases. The sequence of the
promoter controls the binding of the RNA polymerase and transcription factors; therefore these
regions determine where and when the gene of interest will be expressed (106). The leader and
the trailer contain the gene start and the gene stop signals. After transfection of the plasmid
DNA into recipient cells, the plasmid DNAs are transcribed by the corresponding RNA
polymerase to generate a negative-sense minigenome RNA, which is then encapsidated in the
presence of the N. Next, with the help of P and L proteins, an encapsidated sense antiminigenome RNA is produced using the negative-sense encapsidated minigenomic RNA as a
template. The positive strand is in turn used as template to generate the negative strand as a key
step in viral replication. The encapsidated negative RNA strand is transcribed into messenger
RNA (mRNA) lacking the complete 5- and 3- untranslated regions. Finally, the transcribed
mRNA is translated by host-cell machinery to produce the reporter proteins (84).

In a bioluminescent assay, cells are transfected with plasmids encoding for helper plasmids
and the respective luciferase replicon reporter. Luciferase activities are determined 40 hours
post-transfection using a luciferase substrate. Substrates are directly added to the cells and
relative activities are quantified. The reporter protein's activity or fluorescence within a
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transfected cell population is proportional to the steady-state mRNA level and thus gene
expression.

1.6.2

Transcription in the cytoplasm: T7 systems

T7 polymerase has been used for recovery of negative-sense RNA viruses. T7-system
undergoes gene expression and requires entry in cytoplasm. There have been many advantages of
T7-based system: various cell lines (such as Human embryonic kidney (HEK)-293T, Baby
Hamster Kidney (BHK)-T7) can be used that provide exogenous T7 (37). Such permissive cell
lines can be also used for virus recovery but the choice of cell lines in important based on viral
cell tropism. Earlier, cytoplasmic T7 was provided by using recombinant vaccinia virus (78) but
many of its cytopathic effects were found to hamper the T7-dependent system (79). Furthermore,
transiently transfected (89) or stable transfection systems (103) have also been used to prevent
such cytopathic effects.

1.6.3

Transcription in the nucleus: pol I and pol II systems
Three RNA polymerases are present in eukaryotes: 1) RNA polymerase (pol) I

synthesizes the rRNA, without generating 5’caps and 3’tails. 2) pol II synthesizes mRNA and 3)
pol III synthesizes tRNA. Eukaryotic RNA polymerases- pol I and pol III assists cellular
transcription that accounts to 80% of total RNA synthesis. Transcription by pol 1 to synthesize
rRNA is localized to discrete sites called nucleoli (107).
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Transcription of mRNA in mammalian cells via CMV promoter as a viral promoter or
other eukaryotic promoters is dependent on cellular RNA polymerase II. Thus, expression of
foreign genes by such vectors requires the entry of vectors into the nucleus (108).

The pol I-based system has gained attraction over the T7- based system in the
development of reporter assays for segmented RNA viruses like influenza. It was first developed
as a solution to generate this complex recombinant virus as RNA pol-I assists nuclear
transcription (109, 110). Pol-I system has many advantages such as: 1) does not require
exogenous T7 polymerase 2) does not need ribozyme cleavage (106).

1.7

Bicistronic and Tricistronic Reporter Assays
Multicistronic reporter assays can test the negotiation of intergenic junctions by the

RdRp complex in negative sense non-segmented viral genomes. By using such multicistonic
constructs for reporter based assays systems, we could determine if the transcription gradient is
compromised in the subsequent genes. As monocistronic assay system does not consider the
RdRP travel through the intergenic junctions, we were able to identify a system that could be
used for testing the polymerase activity and the successful negotiation of intergenic junctions by
the RdRp complex in negative sense non-segmented viral genomes.
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Figure 6: Schematics of the bi- and tricistronic minigenome plasmids generated
(firefly luciferase; nanoLuc, nanoluciferase; IGS- intergenic segment; Le- leader sequence;
Tr, -trailer sequence; P_stopstop, MeV P protein–encoding ORF harboring a tandem stop
codon after the 21st triplet) (100)

Firtly, the MeV bicistronic replicon was first cloned using monocistronic MeV replicon
(111) as the template. Recombineering PCR technique was performed to generate a bicsistronic
construct cassette that consists of one intergenic junction between two reporters. Secondly, the
bicstronic construct was used as a backbone to generate a tricistronic construct. This construct
had two intergenic junctions placed in between three ORF’s as shown in figure 6.

Limitations: Despite the wide use of the reporter system, there are limitations to this approach.
The viral infectious cycle environment is very different from the intracellular environment for
the plasmid-based expression of helper plasmids. Many types of plasmids need to be transfected
that can limit the efficiency of transfection and target gene expression and the ratio of plasmids
need to be adjusted. Furthermore, a viral minigenome is shorter than its full-length genome.
These limitations should be considered for designing a reporter assay system.
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2

MATERIALS AND METHODS

For additional methods, refer Appendix I: Thakkar V.D., Cox R.M., et al (2018): The
Unstructured Paramyxovirus Nucleocapsid Protein Tail Domain Modulates Viral Pathogenesis
through Regulation of Transcriptase Activity. Journal of Virology.

2.1

Cell Culture
Human embryonic kidney (HEK293, CRL-3216; ATCC), Baby hamster kidney cells (C-

13; ATCC) stably expressing T7 polymerase (BSR-T7/5, (112)) and African green monkey
kidney epithelial cells (CCK-81; ATCC) stably expressing human or canine signaling
lymphocytic activation molecule (Vero-hSLAM and Vero-cSLAM, respectively (113)) were
maintained at 37°C and 5% CO2 in Dulbecco’s modified Eagle’s medium supplemented with
7.5% fetal bovine serum. All stable cell lines were incubated in the presence of G-418 (100
µg/ml) at every fifth passage. GeneJuice (Novagen) reagent was used for all transient
transfections of cells.

2.2

Molecular biology
Plasmids encoding expression constructs of MeV strain Edmonston N, P, and L (103), MeV

strain IC-B N, P, and L (62, 80), CDV strain Onderstepoort N, P, and L (29), and NiV N, P, and
L (114) were previously described. Likewise, plasmids harboring full length cDNA copies of the
MeV strain IC-B genome (62), CDV strain 5804PeH genome (115), the different MeV
minireplicons (100), and shuttle vectors harboring MeV strain IC-B and CDV strain 5804PeH
derived N ORFs were previously reported (80). A cloning strategy developed in our earlier work
(80) was applied to generate all MeV, CDV, or NiV-encoding N genes with internal Ntail
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truncations. Briefly, sets of PCR primers were engineered that flanked the specific nucleotides
targeted for deletion and contained terminal Afe-I restriction sites in frame with the N ORF.
Religation of the Afe-I digested PCR products reconstituted the expression plasmid, now
replacing the targeted Ntail section with Ser-Ala residues encoded by the Afe-I site. All Ntail
modifications were confirmed by DNA sequencing. In addition, all full-length genome plasmids
were sequence-confirmed prior to recovery transfection of recombinant virions. To generate a
NiV nano luciferase minireplicon reporter construct, the Nano luciferase gene was amplified
using appropriate PCR primers and the resulting product cloned into an existing NiV replicon
backbone (114) that was likewise PCR amplified using appropriate primers. The nano-luciferase
amplicon was ligated to the replicon vector backbone using the NeBuilder kit in accordance with
the manufacturer’s protocols (New England Biolabs), and the resulting plasmid sequence
verified.

2.3

Immunoblotting
BSR-T7/5 cells transfected in a 12-well plate format (4x105 per well) with 2 µg of MeV or

CDV N-encoding expression plasmid DNA were washed once 40 hours after transfection with
phosphate buffered saline (PBS) and lysed in RIPA buffer (1% sodium deoxycholate, 1% NP-40,
150 mM NaCl, 50 mM Tris-Cl, pH 7.2, 10 mM EDTA, 50 mM NaF, 0.05% SDS, protease
inhibitors [Roche]. Cleared lysates (20.000xg, 10 min, 4°C) were mixed with 5 x urea buffer
(200 mM Tris, pH 6.8; 8 M urea; 5% sodium dodecyl sulfate (SDS); 0.1 mM EDTA; 0.03%
bromphenol blue; 1.5% dithiothreitol). Samples were denatured for 30 min at 50°C, fractionated
on 10 % SDS-PAGE gels, blotted on polyvinylidene difluoride (PVDF) membranes and
subjected to enhanced chemiluminescence detection using specific antibodies directed against
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MeV-N (MAB8905, Millipore), CDV (DV2-12, Bio-Rad), CDV-N-core (clone 1214) (116) and
GAPDH (6C5, Ambion) as specified. Immunoblots were developed using a ChemiDoc digital
imaging system (Bio-Rad), and the Image Lab software package (Bio-Rad) for image
visualization. When applied, densitometry was carried out on non-saturated images with global
background correction.

2.4

Minireplicon luciferase reporter assay
BSR-T7/5 cells (5,000 in a 96-well plate format) were transfected with plasmids encoding

for IC-B-L (0.02 µg), IC-B-P (0.02 µg), IC-B-N (0.016 µg) and the respective MeV luciferase
replicon reporter (0.044 µg). CDV minireplicon assay were performed accordingly using CDV
helper plasmids. For NiV minireplicon experiments, cells were transfected with NiV-L (0.005
µg), NiV-P (0.005 µg), NiV-N (0.01 µg), and NiV nanoluciferase replicon reporter (0.06 µg)
encoding plasmid DNA. Firefly or nano luciferase activities were determined 40 hours posttransfection in a Synergy H1 microplate reader (BioTek), using Bright-Glo or Nano-Glo
luciferase substrate (Promega), respectively. Substrates were directly added to the cells and
bioluminescence quantified after a 3-minute incubation for signal stabilization. Relative RdRp
activities (relA) were determined on the basis of the formula % relA = (experimental −
signalmin)/(signalmax − signalmin) × 100, with signalmax corresponding to cells transfected with
plasmids encoding the standard NiV proteins and signalmin representing cells that received equal
amounts of empty vector (pUC-19) in place of the N-encoding plasmid. All experiments were
performed in at least 3 independent replicates, each measured in nine dependent repeats.
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2.5

Virus recovery
Recombinant MeV or CDV were recovered in BSR-T7/5 cells by transfecting 1.25 µg of the

cDNA copy of the modified genome and IC-B-N (0.42 µg), IC-B-P (0.54 µg) and IC-B-L (0.55
µg). All recombinant CDV genomes harbored an additional transcription unit encoding the
mKate fluorescent protein in pre-L ORF position, which does not affect viral pathogenicity
(115). Transfected cells were overlaid 48 hours after transfection onto Vero-hSLAM or VerocSLAM cells and emerging infectious particles were passaged in Vero-hSLAM or Vero-cSLAM
cells, respectively. Integrity of newly rescued virus strains was confirmed by extracting total
RNA from infected cells (RNeasy mini kit, Quiagen) and generating cDNA copies using random
hexamer primers and Superscript III reverse transcriptase (Invitrogen). Modified genome regions
were amplified using appropriate primers and subjected to Sanger sequencing.

2.6

Preparation of virus stocks
MeV and CDV virus stocks were prepared by infecting Vero-hSLAM or Vero-cSLAM cells

at a multiplicity of infection (MOI) of 0.01 50% tissue culture infectious dose (TCID50) units per
cell, followed by incubation at 37°C. When microscopically observed virus-induced
cytopathicity reached approximately 90%, cell-associated progeny particles were released
through freeze/thaw cycles and titers determined by TCID50 titration on Vero-hSLAM or VerocSLAM cells as described (117).

2.7

Multi step virus growth curves
Prior to infection for multi-step growth curves, viral stocks were diluted to approximately

1x104 TCID50 units/ml and exact titers determined in a separate aliquot by TCID50 titration.
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Vero-hSLAM or Vero-cSLAM cells (1×105 per well in a 12 well format) were infected with the
different MeV or CDV strains at a MOI of 0.01 TCID50 units per cell for 1 hour and the
inoculum replaced with DMEM growth medium. Individual wells were harvested in 12-hour
intervals and cell-associated progeny virus titers determined by TCID50 titration. At least three
independent growth curves were generated for each virus strain examined. Virus-induced
cytopathicity in infected cells was documented using an inverted fluorescence microscope
(Nikon) equipped with digital imaging package.

3
3.1

RESULTS

RSV minireplicon under pol1 control

(Refer Appendix III: Yan, D., Lee, S., Thakkar,V.D., Luo, M., Moore, M. L., & Plemper, R. K.
(2014): Cross-resistance mechanism of respiratory syncytial virus against structurally diverse
entry inhibitors. PNAS) (118).

Various luciferase reporters are used for a high-throughput screening (HTS) protocol design
that can identify paramyxovirus-speciﬁc, orthomyxovirus-speciﬁc, or broadly specific
compounds in a single assay system (101). The goal was to develop pol-I reporter system for use
in RSV nucleoside analog testing.

As discussed earlier, pol-I system has many advantages such as: 1) the pol I enzyme is
expressed in the nucleolus of all eukaryotic cells and therefore does not need to be provided
in trans. 2) transcripts generated by the pol I constructs have precise viral ends, i.e., they lack the
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5′ cap structure and the 3′ poly A tail (119, 120). 3) the pol I system does not have the potential
inherent disadvantage of vaccinia virus cytopathocity (119, 120).

Experimental Results: Firstly, TOPO-cloning was performed using the RSV primers to
generate RSV leader-Firefly-trailor casette.
RSV forward 5’-CGTCTCCTATTACGAGAAAAAAAAGTGTCAAAAAC-3’
RSV reverse 5’-CGTCTCGGGGGACGGGAAAAAATGCGTACAAC-3’

The resulting product was cloned into an existing replicon by using BsmB-I restriction site.
Based on a described pT7-RSV-luciferase minigenome reporter (121), this RSV minigenome
construct (pHH-RSV-repl-firefly) was generated under the control of the constitutive RNA pol I
promoter (as shown in the figure 7). This construct was then tested using varied amounts (0.82.5ug) for reporter activity in order to test the amount of reporter to be used subsequently. To
determine the relative luciferase reporter activities, Human embryonic kidney (HEK293/293T)
cells were used at 28 and 50h post-transfection because it has high pol-1 activity inherently.
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A
Restriction map of PHH21 minireplicon Firefly .xdna - 4570 nt [using RELibrary as a Restriction Enzyme Library]
<Serial Cloner V2.5> -- <Mar 14, 2018 12:58 PM>

B

Figure 7: Monocistronic pol-1 based RSV minigenome
A.Schematics of the Pol-I minigenome RSV plasmids generated (firefly- firefly luciferase; Le,
leader sequence; Tr, trailer sequence.
B.Graphic map of the pol-I minigenome RSV plasmid generated

RNA pol-I terminator:
AAAAAAAAAAAAAAAAAAAAAAAAAAGAGTCCAGAGTGGCCCCGCCGTTCCGCGC
CGGGGGGGGGGGGGGGGGGGGACACTTTCGGACATCTGGTCGACCTCCAGCATCGG
GGGAAAAAAAAAAAACAAAGTTTCGCCCGGAGTACTGGTCGACCTCCGAAGTTGGG
GGGG
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3’ non-coding- Leader:
agtagaaacaggGTAGATAATCACTCACTGAGTGACATC

Firefly Luciferase- ORF:
atggaagacgccaaaaacataaagaaaggcccggcgccattctatcctctagaggatggaaccgctggagagcaactgcata
aggctatgaagagatacgccctggttcctggaacaattgcttttacagatgcacatatcgaggtgaacatcacgtacgcggaatacttcgaaa
tgtccgttcggttggcagaagctatgaaacgatatgggctgaatacaaatcacagaatcgtcgtatgcagtgaaaactctcttcaattctttatg
ccggtgttgggcgcgttatttatcggagttgcagttgcgcccgcgaacgacatttataatgaacgtgaattgctcaacagtatgaacatttcgc
agcctaccgtagtgtttgtttccaaaaaggggttgcaaaaaattttgaacgtgcaaaaaaaattaccaataatccagaaaattattatcatggatt
ctaaaacggattaccagggatttcagtcgatgtacacgttcgtcacatctcatctacctcccggttttaatgaatacgattttgtaccagagtcctt
tgatcgtgacaaaacaattgcactgataatgaattcctctggatctactgggttacctaagggtgtggcccttccgcatagaactgcctgcgtc
agattctcgcatgccagagatcctatttttggcaatcaaatcattccggatactgcgattttaagtgttgttccattccatcacggttttggaatgttt
actacactcggatatttgatatgtggatttcgagtcgtcttaatgtatagatttgaagaagagctgtttttacgatcccttcaggattacaaaattca
aagtgcgttgctagtaccaaccctattttcattcttcgccaaaagcactctgattgacaaatacgatttatctaatttacacgaaattgcttctggg
ggcgcacctctttcgaaagaagtcggggaagcggttgcaaaacgcttccatcttccagggatacgacaaggatatgggctcactgagacta
catcagctattctgattacacccgagggggatgataaaccgggcgcggtcggtaaagttgttccattttttgaagcgaaggttgtggatctgg
ataccgggaaaacgctgggcgttaatcagagaggcgaattatgtgtcagaggacctatgattatgtccggttatgtaaacaatccggaagcg
accaacgccttgattgacaaggatggatggctacattctggagacatagcttactgggacgaagacgaacacttcttcatagttgaccgcttg
aagtctttaattaaatacaaaggatatcaggtggcccccgctgaattggaatcgatattgttacaacaccccaacatcttcgacgcgggcgtg
gcaggtcttcccgacgatgacgccggtgaacttcccgccgccgttgttgttttggagcacggaaagacgatgacggaaaaagagatcgtg
gattacgtcgccagtcaagtaacaaccgcgaaaaagttgcgcggaggagttgtgtttgtggacgaagtaccgaaaggtcttaccggaaaac
tcgacgcaagaaaaatcagagagatcctcataaaggccaagaagggcggaaagtccaaattgtaa
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5’ non-coding- Trailer:
AGAAAAATACccttgcttctact

RNA pol-I promoter:
aataACCCGGCGGCCCAAA

HEK293/293T cells were cotransfected with 0.8ug, 1.5ug, 2ug or 2.5ug pol-I reporter with
optimized ratios of RSV helper plasmids (N, P, M2 (0.4ug/well each) and L (0.2ug/well)) under
CMV promoter control (122). Luciferase reporter activities were determined at 28 and 50 h after
transfection activity in order to test the amount of reporter to be used subsequently.

Figure 8: Minireplicon analysis of a firefly luciferase-RSV reporter in 293T cell line
at 28 and 50h post-transfection.
Activity represents relative luciferase reporter activities. Values represent averages of two
dependent experiment, determined as ± SD.
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The pol-I reporter was reported to be active with 2ug at 50 hours post transfection as shown in
the figure 8. This experiment showed technical errors as the reporter showed increasing activity
with increasing amounts of reporter for 28 hours post transfection. This was not observed for 50
hours post infection activity profile. But this reporter was active and was used further in RSV
reporter assays in nucleoside analog testing.

3.2

Polycistronic minireplicons

(Refer Appendix II: Cox, R. M., Krumm, S. A., Thakkar,V.D., Sohn, M., & Plemper, R. K.
(2017): The structurally disordered paramyxovirus nucleocapsid protein tail domain is a
regulator of the mRNA transcription gradient. Science Advances)

The natural paramyxovirus transcription gradient of mRNA synthesis has been shown to
affect by the structurally disordered central Ntail section through two synergistic effects- 1)
promoting the initiation of the transcriptase complex and 2) reducing the success of the
transcriptase to negotiate the entire genome (123). To address whether N-tail mutants allow
RdRp to efficiently negotiate the intergenic junctions in the viral genome, a process that involves
the nontemplated polyadenylation of the newly synthesized mRNA, migration of the RdRp
complex to the next downstream transcription start sequence, and reinitiation of RNA synthesis,
we generated a novel firefly luciferase and nanoluciferase bi- and tricistronic minigenome
reporter plasmids.

Pseudotemplated addition of nucleotides or RNA editing, as described earlier, occurs in P.
The P reading frame was chosen because of its RNA editing site, which makes the RdRp stutter
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and may enhance the likelihood for premature termination of replication in order to evaluate the
successful negotiation of intergenic junctions and to determine the polymerase activity of
different MeV N-tail mutants in Morbilliviruses with the help of multicistronic minireplicons
since the monocistronic minireplicons cannot address this question.

The bicistronic reporter harbors the N/P open reading frame (ORF) intergenic junction of the
MeV genome between the luciferase reporter genes, whereas the tricistronic plasmids contains
the entire MeV P ORF including the N/P and P/M intergenic junctions. Firstly, the MeV
bicistronic replicon was cloned using monocistronic MeV replicon (111) as the template.
Recombineering PCR technique was used with the help of Aat II and Avr II sites to create a
firefly luciferase–(P/M-IGS)–gaussi cassette. But, this bicistronic construct did not show any
appreciable activity for the Gaussi luciferase reporter and the construct was then exchanged for
the nanoluciferase reporter construct. By cloning with the help of Pac I and Avr II sites, this
bicistronic cassette was introduced it into an existing monocistronic MeV minigenome (111).

The bicistronic construct served as the backbone for the tricistronic variant. Again by
recombineering PCR, a second intergenic junction cassette was cloned into the former with the
help of Pac I and Aat II sites. An eGFP protein (with the same intergenic junctions as the others
N-P and P-M), Pstopstop or P_ORF_without the editing site-(1200bp shorter) P-(ΔCV) was
placed as the 2nd ORF in between two intergenic junctions. In the case of Pstopstop, a tandem
stop codon was introduced into the ORF to avoid influencing minireplicon activity through
additional P protein originating from the tricistronic minigenome, The stop codon was inserted
21 triplets downstream of the start codon.
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Figure 9: Bi- and Tricistronic minigenome assays -quantitating negotiation of intergenic
junctions in the presence of transiently expressed MeV N standard and mutant plasmid
MeV NΔ439-482.
(contributed by K.Wabbel and R.K.P- from Institute for Biomedical Sciences, Georgia State
University)
A) Minireplicon analysis of the MeV N mutant using a Bicistronic minigenome reporter.
Activity represents normalized (to the mutant) ratio – second ORF (nano luciferase) versus first
ORF (firefly luciferase) reporter activities of each biological replicate. Values represent averages
of at least three independent experiments, determined in nonuplets each ± SEM. Shown is a
comparison of two out of three data sets generated. Experimental variation was assessed through
one-way analysis of variance (ANOVA) combined with Tukey’s multiple comparison post test
(*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant). B) Schematic of the tricistronic
minigenome plasmids generated (firefly, firefly luciferase; nanoLuc, nanoluciferase; IGS,
intergenic segment; Le, leader sequence; Tr, trailer sequence; eGFP, P_stopstop and P-ORF –
without the non-structural proteins C and V – P-(ΔCV) – 2nd ORF. C) Minireplicon analysis of
the MeV N mutant using a Tri-cistronic minigenome reporter. Activity represents normalized (to
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the mutant) ratio- third ORF (nano luciferase) versus first ORF (firefly luciferase) reporter
activities of each biological replicate. Values represent averages of at least three independent
experiments, determined in nonuplets each ± SEM. Experimental variation was assessed through
one-way analysis of variance (ANOVA) combined with Tukey’s multiple comparison post-test
(*P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant).

Bi- and Tricistronic minigenome reporter assay measures the negotiation of intergenic
junctions in the presence of the MeV-N mutant was first tested as above (figure 9). In this
protocol, BHK-T7 cells were cotransfected with either reporter and helper plasmids under T7
promoter control. For analysis of the minigenome data, data sets obtained for each reporter were
normalized in the presence of the mutant N. Later, the ratios of normalized nanoluciferase versus
firefly luciferase signals for standard N was calculated. In the presence of the different
constructs, this kind of approach enables us to appreciate the relative efficiency with which the
RdRp complex accesses the downstream relative to the upstream reporter.

In case of bicistronic construct, the relative reporter expression levels of MeV N-(Δ439482) were higher than standard N. In the case of tricistronic P-stopstop construct, the relative
reporter expression levels did not differ significantly. For viral foreign proteins like eGFP and a
highly truncated P that lacks the reading frames for C and V – (P-(ΔCV), significantly lower
transcription efficiency in the presence of the N mutant was observed. Whether this finding is
due to the shortened reading frames (both tricistronic constructs are shorter than the original P
ORF) or due to RdRp processivity is further needed to be determined. It was demonstrated that
through minireplicon assays that the mutant N did not affect RNA editing in the P open reading
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frame. These results show that the non-structural proteins C and V do not influence the
multicistronic RdRp activity and also shows successful negotiation of intergenic junctions by the
RdRp complex in the absence of the unstructured morbilliviral Ntail section.

3.3

Paramyxovirus Nucleocapsid Protein Tail Domain Modulation

The functional importance of the structurally disordered central Ntail sections for paramyxovirus
polymerase activity is currently mechanistically poorly understood, although it was thought that
it provides structural flexibility to MoRE for recruitment of the polymerase complex (124, 125).

Figure 10: Schematic of the morbillivirus Ntail organization
(model by R. M Cox - from Institute for Biomedical Sciences, Georgia State University)
A) Model of the full-length measles N protein. The Ntail domain (134 amino acids) missing
from the cryoEM reconstruction of Ncore (blue-grey; PDB 4UFT) was added using Coot for
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relative length illustration only. Conserved box regions are highlighted in yellow, orange, and
green according to their position in the linear sequence. Heat maps (red) represented the
predicted degree of structural disorder. Cartoon representations of the assembled MeV
nucleocapsid assume a perpendicular orientation of Ntail to the axis of the helical RNP assembly
(right). Ntail originates at the inner surface of the RNP and box1 residues are predicted to be
buried between the rungs of the helix. B, C) Models of Ntail mutants after partial (B) or nearly
complete (C) removal of the disordered central Ntail section. The truncations posit box2 and 3
regions in close proximity to the trunk of the RNP assembly. D) Sequence alignment of the MeV
and CDV Ntail domains. Box1-3 domains are color-coded as described in (A). Truncation donor
(red) and acceptor (green) residues explored in this study are highlighted. Alignments were
generated using T-Coffee [69] and structural models of MeV Ntail variants created in Pymol
[70].

To test whether the morbillivirus unstructured central Ntail section is required for virus
replication, we first designed a series of progressively larger internal tail deletions in MeV N,
commencing with the removal of residues between positions 439 and 482, located just upstream
of the conserved MoRE and box3 and extending to elimination of most of the structurally
disordered residues between box1 and MoRE (figures 10A-C). Figure 10D provides an overview
of all morbillivirus (MeV and CDV) Ntail truncations targeted. The largest deletion in MeV N
eliminated all of Ntail between residues 399 and 482, which also includes the conserved box1
region at the N-terminal origin of the tail. Naturally, gradual removal of the central Ntail residues
will position the C-terminal end of Ntail harboring MoRE and box3 in immediate proximity of
the trunk of the helical RNP assembly, ultimately predicting the placement of MoRE
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immediately proximal to the interface between consecutive turns of the RNP helix.

Figure 11: Bioactivity of MeV and CDV N protein mutants with different length deletions
in the disordered central tail section.
A, C) Steady state levels of MeV (A) and CDV N (C) protein mutants in cells BHK-T7 cells
transfected with N protein-encoding plasmid DNA. Immunoblots were decorated with specific
antibodies directed against MeV and CDV N protein, respectively, or cellular GAPDH for
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sample processing control. Numbers represent means of densitometry quantitations of three
biological repeats ± SEM; all uncropped blots are shown in supplementary figures 5 and 6. B,
D) Monocistronic minigenome assays testing bioactivity of the N protein mutants specified in
(A) and (C). Symbols represent relative luciferase units of each biological replicate, determined
each in nine technical replicates and normalized for values measured for standard N protein.
Columns show sample means ± SEM; P values are based on one-way ANOVA with Tukey’s
multiple comparison post hoc test, F: 18.1 (B) and 37 (D). E, F) Tricistronic minigenome assays
-quantitating negotiation of intergenic junctions in the presence of the N protein mutants
(contributed by K.Wabbel, J. Sourimant and R.K.P- from Institute for Biomedical Sciences,
Georgia State University). Symbols represent third ORF (nano luciferase) versus first ORF
(firefly luciferase) reporter activities of each biological replicate, each measured in nine technical
replicates. Columns show samples means ± SEM; P values are based on one-way ANOVA with
Tukey’s multiple comparison post hoc test, F: 30.6 (E) and 4.8 (F); NS: not significant).

Western blot analyses of cell lysates after transient transfection with plasmids encoding these
mutants confirmed stable expression of all modified N proteins and revealed a gradual increase
in electrophoretic mobility with expanding truncation size as anticipated (figure 11A). The two
constructs harboring partial or complete deletions of box1 (NΔ399-482 and NΔ409-482),
resulted in substantially reduced or no appreciable minireplicon activity, respectively. All other
mutants supported efficient RdRp activity in a monocistronic minireplicon reporter assay (figure
11B). While average relative RdRp activities varied slightly compared to those observed in the
presence of standard MeV N, none of these changes was statistically significant.
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Encouraged by these results, we generated a comparable series of CDV N deletion mutants
informed by the Ntail linear sequence alignments as outlined (figure 10D). Resembling the
corresponding MeV N mutants, expression levels and bioactivity of CDV NΔ441-479 and
NΔ425-479 was indistinguishable from that of standard CDV N in Western blotting and
minireplicon assays (figures 11C and D). However, larger truncations (CDV NΔ423-479 and
NΔ421-479, respectively) resulted in significantly enhanced minireplicon activities. As noted for
MeV, truncation encroaching into the box1 section abolished CDV N bioactivity.

Since monocistronic minireplicons cannot address whether the viral transcriptase retains the
ability to successfully negotiate intergenic junctions, we employed a tricistronic minireplicon
construct that contains two intergenic junctions and distinct firefly and nano luciferase reporter
genes in the first and third reading frame position, respectively. In this assay, the relative ratio of
downstream versus upstream reporter activity serves as an indicator for the efficiency with which
the RdRp complex advances through intergenic junctions and reinitiates mRNA synthesis. When
tested in the presence of a subset of the MeV (figure 11E) and CDV (figure 11F) Ntail mutants,
only the MeV NΔ420-482 construct returned a slight (approximately 25%) but statistically
significant relative reduction of third ORF expression. In the presence of all other constructs,
relative reporter expression levels did not differ significantly from those observed with standard
N, suggesting successful negotiation of intergenic junctions by the RdRp complex in the absence
of the unstructured Ntail section.
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Figure 12: Bioactivity of corresponding Henipavirus N protein mutants
(performed in assistance with R. M Cox, Institute for Biomedical Sciences, Georgia State
University)
A) Schematic of the NiV Ntail organization and disorder prediction, color-coded as in
supplementary figure 1A. Ntail truncations eliminate the predicted helical box4 near the center of
Ntail. B) Sequence alignment of the MeV and NiV Ntail domains, color-coded as in (A). The
individual truncation donor (red) and acceptor (green) sites are highlighted. Alignments were
generated using T-Coffee. C) Minigenome activity analysis of the NiV N protein mutants.
Symbols represent individual biological replicates, each determined in nine technical replicates.
Columns show sample means ± SEM; P values are based on one-way ANOVA with Tukey’s
multiple comparison post hoc test, F: 19.1; df1: 2, df2: 6.

To evaluate whether continued RdRp activity in the absence of the central Ntail section extends
to paramyxoviruses outside the morbillivirus genus, we applied an equivalent truncation strategy
to the Ntail of highly pathogenic NiV, a member of the recently established henipavirus genus
(figures 12A and B). Although the organization of the NiV tail is predicted to be more complex
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than that of the morbilliviruses, featuring an additional box4 in the central Ntail section (126),
NiV RdRp also readily accepted template RNA encapsidated by tail-truncated N (figure 12C).
Whereas a NiV NΔ424-471 mutant protein with large truncation showed standard NiV N-like
activity in minireplicon assays, bioactivity of the NiV N construct harboring a shorter NΔ443471 truncation was also significantly increased.
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Figure 13: Recovery of recombinant MeV and CDV expressing N protein mutants.
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A, B) Electrophoretic mobility profiles of N proteins expressed by the different recMeV (A) and
recCDV (B) strains. Whole cell lysates of infected Vero-hSLAM and Vero-cSLAM cells,
respectively, were subjected to immunoblotting and detection with specific antibodies directed
against the MeV or CDV N protein. C, F) Multi-step growth curves of the different recMeV (C)
and recCDV (F) strains recovered. Vero-hSLAM and Vero-cSLAM cells, respectively, were
infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of cellassociated progeny virus at the indicated time points. Values represent means of three
independent experiments ± SEM. D, G) Regression modeling of growth profiles shown in (C)
and (F). (contributed by R.K.P- from Institute for Biomedical Sciences, Georgia State
University). Bindslev’s population growth four-parameter variable slope model was applied
(PDTmax, maximal population doubling time; Titermax, titer corresponding to the top plateau of
the regression models; values in parentheses specify 95% confidence intervals; * denotes nonoverlapping confidence intervals relative to standard recMeV; NS, overlapping confidence
intervals). E, H) Cytopathic effect associated with the different recMeV and recCDV strains
(contributed by R.M Cox- from Institute for Biomedical Sciences, Georgia State University).
Microphotographs of infected cells were taken at the specified times post-infection at a
magnification of 200×.

RdRp activity in minireplicon assays is a necessary albeit not sufficient function to support a full
viral replication cycle. We also substituted the N protein encoding ORFs in cDNA genome
copies of MeV and CDV strains that are based on pathogenic viral isolates, MeV-IC-B (62) and
CDV-5804PeH (115), with two different Ntail truncations each, MeV NΔ439-482 and NΔ420482, and CDV NΔ441-479 and NΔ425-479, respectively. These specific truncations were
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selected on the basis that in each case they represent the shortest and largest internal tail
truncation that did not significantly alter N bioactivity in the original monocistronic minireplicon
assay. The corresponding recombinant viruses were recovered readily after rescue transfection
and overlay onto receptor-positive Vero-humanSLAM (Vero-hSLAM) and Vero-canineSLAM
(Vero-cSLAM) cells, respectively. DNA sequencing after RT-PCR amplification of recovered
virus genomes and Western blot analyses of infected cell lysates (figures 13A and B) confirmed
the presence of the respective Ntail truncations in the recombinant viruses.

Multiple step growth curves revealed a parent virus-like replication profile for recMeV-IC-B
NΔ439-482 (figure 13C), whereas recMeV-IC-B NΔ420-482 with the larger Ntail truncation
showed an initial 12-hour growth delay. Modeling of growth profiles confirmed that maximal
population doubling times of recMeV-IC-B NΔ420-482 were significantly longer than those of
standard recMeV-IC-B, but differences between recMeV-IC-B NΔ439-482 and the parent strain
remained not significant (figure 13D). Microphotographs of the infected cell populations at
different times after infection demonstrated that cytopathic effects corroborated the virus titerbased growth profiles (figure 13E). Interestingly, the growth pattern of the MeV mutants was
inversed in the case of the recombinant CDV virus strains (figure 13F). recCDV-5804PeH
NΔ425-479 carrying the larger truncation showed significantly shorter maximal doubling times
than recCDV-5804PeH NΔ441-479 (figure 13G). However, maximal growth rates of both
mutant strains lagged behind that of the parental recCDV-5804PeH, although growth profile
modeling did not reveal significant differences in peak progeny titers reached. Visual
examination of viral cytopathicity again showed only small differences between the two mutant
strains and the parental recCDV (figure 13H).
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These data demonstrate that the unstructured central Ntail section is not associated with an
essential RdRp function required for virus replication, establish distinct effects of different
length truncations on viral fitness in cell culture, and indicate that the actual impact of internal
Ntail truncations on virus growth is not necessarily directly proportional to the length of the
deletion but must be individually determined.

Figure 14: Pathogenesis of the recCDV mutants in the ferret model
(contributed by B. Sawatsky, and V. Messling- from Veterinary Medicine Division, Paul-EhrlichInstitut, Federal Institute for Vaccines and Biomedicines, Langen, Germany and R. Budaszewski-
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from Paul-Ehrlich-Institut and Federal University of Rio Grande do Sul, Porto Alegre, Brazil)
A) Cell-associated viremia titers after intranasal infection of animals with the different recCDV
strains. Symbols represent TCID50 units in 106 isolated PBMCs for each biological replicate;
lines connect sample means (recCDV NΔ425-479-infected animals n = 4; recCDV NΔ441-479infected animals n = 7; recCDV-5804PeH-infected animals n = 4); P values are based on twoway ANOVA with Tukey’s multiple comparison post hoc test; F: 2.9; df1: 2, df2: 10. B)
Survival curves. Statistical significance of differences between the curves was assessed through
Mantel-Cox test, predicted median survival is shown; df: 2. C) Virulence index for standard and
mutant recCDV-5804PeH strains. Each box represents one animal, clinical score index ranges
from high (black), to intermediate (grey) and absent (white). D) Body weight changes in the
infected animals. Weight is expressed as the percentage of the initial weight at the day of
infection. Symbols represent individual biological replicates; lines connect sample means; P
values are based on two-way ANOVA with Sidak’s multiple comparison post hoc test; F: 7.5;
df1: 1, df2: 9. E) Fever curves of infected animals. Symbols represent body temperature for each
biological replicate; lines connect sample means; P values are based on two-way ANOVA with
Sidak’s multiple comparison post hoc test; F: 38; df1: 1, df2: 189. F) Lymphopenia assessment.
Symbols represent mean leukocyte counts per cubic millimeter of blood for each biological
replicate; lines connect sample means; P values are based on two-way ANOVA with Tukey’s
multiple comparison post hoc test; F: 0.91; df1: 2, df2: 10. G) Nonspecific PBMC proliferation
capacity. Symbols represent mean rations of 5-bromo-2’ deoxyuridine (BrdU) incorporation
relative to nonstimulated PBMCs for each biological replicate; lines connect sample means; P
values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test; F: 0.42;
df1: 2, df2: 11.
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To evaluate the importance of Ntail for viral pathogenesis, we capitalized on the lethal
CDV/ferret model that recapitulates key features of human morbillivirus disease such as host
invasion strategy, tissue tropism, and replication profile (127). Ferrets were infected intranasally
with 2×105 TCID50 units of standard recCDV-5804PeH, recCDV-5804PeH NΔ441-479, or
recCDV-5804PeH NΔ425-479, and clinical signs, PBMC-associated viremia titers, white blood
cell counts, and lymphocyte proliferation response were monitored in regular intervals.
Consistent with our previous experiences with the model (128), peak viremia titers were reached
seven days post-infection, followed by a rapid decline in viral load in animals infected with
either of the N mutant viruses (figure 14A). All animals infected with standard recCDV5804PeH succumbed to the disease by day 14. By contrast, the group that had received recCDV5804PeH NΔ441-479 and 75% of animals in the recCDV-5804PeH NΔ425-479 group survived
the infection (figure 14B). In recovering animals, viremia fully subsided 21 (recCDV-5804PeH
NΔ441-479) and 35 (recCDV-5804PeH NΔ425-479) days after infection, respectively.

Animals infected with the parental virus experienced severe disease with extensive rash,
substantial weight loss, and high fever (figures 14C-E). By comparison, disease progression was
less aggressive in animals infected with the recCDV-5804PeH NΔ425-479 mutant virus and mild
in animals of the recCDV-5804PeH NΔ441-479 group. Specifically, recCDV-5804PeH NΔ441479-infected ferrets showed a benign, more localized rash and only transiently lost a moderate
(<10%) amount of body weight before making a full recovery by conclusion of the study (figure
11D). Fever peaked in these animals two to three days earlier and at a lower level than in
recCDV-5804PeH and recCDV-5804PeH NΔ425-479-infected animals, and resolved within the
second week after infection (figure 14E). In contrast, recCDV-5804PeH NΔ425-479 infected
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ferrets presented with a more prolonged weight loss and fever fully resolved only in the third
week after infection.

Acute lymphopenia and temporary lack of lymphocyte responsiveness to stimulation constitute a
hallmark complication associated with morbillivirus infections (129). When assessing immune
competence of animals infected with the different viruses, we noted significantly milder
lymphopenia early after infection in the recCDV-5804PeH NΔ441-479 group compared to
animals that had received standard recCDV-5804PeH or recCDV-5804PeH NΔ425-479 (figure
14F). However, lymphocytes derived from animals of all groups showed a similar decline in
proliferation responsiveness during the first two weeks after infection (figure 14G). Proliferation
response improved in all surviving animals only at 35 days post-infection, although we noted a
temporary rebound in recCDV-5804PeH NΔ441-479-infected ferrets at the 21-day time point.
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Figure 15: Immune responses to recombinant Ntail deletion mutant viruses
(contributed by B. Sawatsky, and V. von Messling- from Veterinary Medicine Division, PaulEhrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany and R.
Budaszewski- from Paul-Ehrlich-Institut and Federal University of Rio Grande do Sul, Porto
Alegre, Brazil)
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A) Relative levels of type I IFN and Mx-1 message present in PBMCs isolated at days three and
seven after infection of animals with the different CDV recombinants. Symbols represent the
relative fold-change in mRNA level normalized to uninfected naive controls (day 0) for each
biological replicate. Horizontal lines and error bars represent mean values ± SEM; t-tests were
used for pairwise comparisons; one-way ANOVA with Sidak’s multiple comparison post hoc
test was applied to Mx-1 day 7 fold-change analysis; F: 1.96; df1: 8, df2: 27. B) Neutralizing
antibody responses in plasma samples. Antibody titers are shown as the reciprocal of the highest
dilution in which CPE was observed. Symbols represent individual biological replicates, lines
connect sample means. P values are based on two-way ANOVA with Sidak’s multiple
comparison post hoc test; F: 4.1; df1: 1, df2: 6. C) Intranasal challenge of surviving animals
from figure 4 with 2 x 105 TCID50 units of standard recCDV-5804PeH. Survival curves of
animals after rechallenge at day 49 post-infection. For comparison, CDV-naïve ferrets were
challenged in parallel (n = 3: recCDV NΔ425-479; n = 4: recCDV NΔ441-479; n = 4: recCDV5804PeH). D) Cell-associated viremia titers in rechallenged animals. Symbols represent
TCID50 units in 106 isolated PBMCs for each biological replicate, lines connect sample means;
P values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test; F:
1448; df1: 2, df2: 8. E) Lymphopenia assessment in rechallenged animals. Symbols represent
leukocyte counts per cubic millimeter of blood for each biological replicate, lines connect sample
means; P values are based on two-way ANOVA with Tukey’s multiple comparison post hoc test;
F: 60.4; df1: 2, df2: 8.
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Animals infected with either mutant virus mounted comparable type I interferon responses,
reaching approximately 10-fold induction levels in IFN-α, β and Mx-1 message, the latter
representing one of the major interferon-stimulated genes in response to CDV infection (figure
15A).

In the same manner, anti-CDV -5804PeH antibody responses were robust in animals of either
group, although interestingly neutralizing antibody titers induced by the more attenuated
recCDV-5804PeH NΔ441-479 peaked slightly higher than those found in animals of the
recCDV-5804PeH NΔ425-479 group (figure 15B). To determine whether antibody titers
mounted by the surviving animals infected with the Ntail modified recombinants were
protective, we re-challenged with a lethal dose of standard recCDV-5804PeH at 49 days after the
original infection. All challenged animals survived (figure 15C) and none developed appreciable
viremia (figure 15D), showed clinical signs, or experienced severe lymphopenia (figure 15E).

These results highlight a role of the unstructured Ntail section in paramyxovirus pathogenesis.
Gradual shortening of the tail induces different degrees of viral attenuation, although not with
direct proportionality. Importantly, all surviving animals in the CDV/ferret model were
completely protected against a lethal challenge with standard CDV, underscoring efficient
immunization by the Ntail-modified recombinant strains.
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Table 1: Sequence analysis of recCDV strains after passage in cell culture and through
ferrets
(contributed by N. Makhsous, A. Greninger- from Virology Division, Department of Laboratory
Medicine, University of Washington, Seattle, WA and with M. Russ and J. Sourimant- from
Institute for Biomedical Sciences, Georgia State University)

To assess the genetic stability of the recCDV with Ntail truncations, we subjected viral RNA
preparations to deep sequencing before and after 10-11 passages in cell culture, and determined
N ORF consensus sequences in viral RNA extracted from PBMCs harvested from ferrets seven
days after infection through Sanger sequencing (table 1). Neither standard recCDV-5804PeH nor
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recCDV-5804PeH NΔ441-479 showed any changes in the N nor P ORF compared to the genome
cDNA plasmids that were used for virus recovery. In contrast, recCDV-5804PeH NΔ425-479
carried a glutamate to glutamine substitution at N residue 156 that was dominant in the viral
population after four passages in cell culture, and acquired an alanine to aspartate exchange at N
residue 410 that became increasingly fixed during cell culture passaging. All recCDV-5804PeH
NΔ425-479 recovered from infected ferrets at the peak of viremia likewise contained both N
substitutions.

Comparison with N sequences representing a variety of different circulating CDV strains and
isolates revealed that the N ORF is fully sequence conserved at position 156 and shows only
more conservative changes than the aspartate substitution at residue 410 (figure 16).
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Figure 16: Alignment of a diverse pool of CDV N sequences representing clinical
viral isolates and laboratory-adapted strains.
(analyses by R.K.P, Institute for Biomedical Sciences, Georgia State University)
Shown are strain identifiers, database access codes, and the areas surrounding the two residues in
the N protein (156 and 410, respectively) featured in table 1. Alignments were created using TCoffee and outputs rendered with ESPript 3.0.

None of the mutants or standard recCDV harbored any coding mutations in the P and L
ORFs, with the exception of a single recCDV-5804PeH NΔ441-479 passaging line that carried a
leucine to proline substitution at L residue 2175 with approximately 50% allele frequency after
15 passages in cell culture (table 1). Since none of the other recCDV-5804PeH NΔ441-479 lines
analyzed in parallel showed allele variation at this position, this mutation most likely represents a
stochastic event that became partially fixed in the genome.
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Figure 17: Analysis of RNA populations present in cells infected with Ntail mutant viruses
in comparison with the parental strain.
(contributed by R. M Cox, Institute for Biomedical Sciences, Georgia State University)
A, B) MiSeq analysis of viral mRNA editing in the P ORF after infection of cells with recCDV
NΔ441-479 (A), recMeV NΔ439-482 (B), or the corresponding parent virus strains. Values
represent a minimum of 91,741 reads each and are expressed as mean percentage of the
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differentially edited mRNAs relative to the total transcripts from the P ORF ± SEM. C) qRTPCR quantitation of relative CDV genome copy numbers in cells infected with the recCDV Ntail
mutants compared to standard recCDV. First strand synthesis with specific primers directed at
the viral genome UTR, followed by amplification of a section of the N ORF. D, E) qRT-PCR
quantitation of relative CDV N mRNA (D) and L mRNA (E) copy numbers present in RNA
preparations as in (C), compared preparations from cells infected with standard recCDV. First
stand synthesis with oligo(dT) primers, followed by amplification of sections of the N and L
ORF. F to H) qRT-PCR quantitations of RNA preparations as in (C) of the relative ratios of L
versus N encoding mRNAs (F), and of intergenic sequence (IGS) N/P (G) and mKate/L (H)
encoding polycistronic mRNAs versus mRNAs encoding the IGS-preceding ORF. First stand
synthesis with oligo(dT) primers, followed by amplification of sections of the N, mKate, and L
ORF, respectively, or across the specified IGS sections. In (C) to (H), symbols represent
individual values of three biological repeats analyzed in two technical repeats each. Columns
show mean values ± SEM. P values are based on one-way ANOVAs with Tukey’s multiple
comparison post hoc test; F ratios and df values are shown for each graph.

To further elucidate the mechanistic basis for the altered CDV pathogenesis profiles, we
analyzed viral RNA populations synthesized in cells infected with the different recombinant
virus strains. Co-transcriptional paramyxovirus mRNA editing results in the expression of two
additional proteins, V and W, from the viral P ORF through the insertion of non-templated G
residues at an editing site (130-133). Of these P ORF products, the CDV V protein serves as the
major suppressor of the host-cell innate antiviral response. RNA editing is thought to result from
backsliding of the RdRp complex on the RNP template (130, 134, 135), which requires structural
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flexibility that could be mediated by the flexible central Ntail section. Since impaired V protein
expression causes viral attenuation (136), we employed a MiSeq assay to quantify the relative
ratios of P, V and W-encoding mRNAs in infected cells. recCDV-5804PeH NΔ441-479 and the
corresponding recMeV-IC-B-NΔ439-482 were selected for this analysis based on the superior
level of attenuation of this shorter CDV truncation mutant in the ferret model. Relative mRNA
distributions were comparable between MeV and CDV, but we noted only minor changes when
mutant and the corresponding parent viruses were compared (figures 17A and B).

Our recent characterization of an MeV recombinant that expressed a mutant N with MoRE
relocated into Ncore and partially truncated tail revealed a steepened viral mRNA transcription
gradient in infected cells (100). However, this MeV recombinant was temperature-sensitive and
unable to replicate under physiological conditions. Based on this finding, we hypothesized that
attenuation of the recCDV Ntail mutants in the ferret model may alternatively result from
deregulated viral transcriptase activity, although more subtle than that experienced with the
MoRE-relocated MeV recombinant. Using an RT-qPCR-based approach, we quantified viral
genome copies in infected cells, determined relative N-encoding and L-encoding mRNA levels
in cells infected with the mutant versus parental virus strains, examined relative ratios of L
protein to N protein-encoding mRNAs produced by each virus strain, and calculated the relative
frequencies with which polycistronic viral mRNAs are synthesized by each recombinant during
replication.

Viral genome copy numbers of both mutant recCDV strains were reduced by approximately 19
to 29% at the end of the replication cycle compared to standard recCDV (figure 17C). By
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contrast, N protein-encoding mRNA levels of either mutant strain were increased approximately
1.8-fold relative to standard recCDV (figure 17D). Interestingly, when we examined relative
mRNA levels of the downstream-most positioned L protein ORF, we noted that this 1.8-fold
increase was maintained in recCDV-5804PeH NΔ425-479 infected cells, but boosted to an
approximately 3-fold relative excess in cells harboring recCDV-5804PeH NΔ441-479 (figure
17E). Analyzing ratios of L protein-encoding versus N protein-encoding mRNAs synthesized by
each virus strain revealed a significant increase in relative amounts of L protein-encoding
mRNAs only in cells infected with recCDV-5804PeH NΔ441-479, while essentially identical
ratios were obtained for standard recCDV and the less attenuated recCDV-5804peH NΔ425-479
(figure 17F).

The higher relative L mRNA level produced by recCDV-5804PeH NΔ441-479 could reflect a
relative increase in bona fide L message due to a lowered premature termination ratio of the
advancing polymerase complex or due to a higher proportion of non-productive polycistronic
mRNAs. To differentiate between these alternatives, we evaluated the relative content of
polycistronic message generated at the first (figure 17G) and last (figure 17H) intergenic
sequence (IGS) present in the recCDV genomes. Depending on the individual IGS examined,
replication of the standard recCDV-5804PeH and recCDV-5804P NΔ425-479 strains resulted in
the synthesis of 2-10% polycistronic message relative to the total message synthesized for the
preceding ORF. At either IGS, however, we noted a significantly higher ratio of polycistronic
message present in cells infected with the recCDV-5804PeH NΔ441-479 mutant strain.
Sequence analysis of the polycistronic message after RT-PCR amplification of an N/P message
fragment harboring the IGS revealed straight read-throughs of the transcriptase complex, lacking
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any non-templated residues at the poly-adenylation site. These results implicate the structurally
disordered central Ntail section in affecting paramyxovirus transcriptase function on two
different levels. Both Ntail mutant strains show heightened transcriptase activity relative to the
parental recCDV strain. In addition, the more severely attenuated recCDV-5804peH NΔ441-479
further disturbs the relative ratio of viral message in infected cells by generating a higher
proportion of non-productive polycistronic mRNAs.

Figure 18: Predicted location of candidate compensatory mutation to the ND425-479
truncation in a model of the CDV RNP assembly.
(model by R. M Cox, Institute for Biomedical Sciences, Georgia State University)
A) The E156Q mutation (red spheres) in Ncore is located near the position at which Ntails
(yellow circles) are postulated to protrude from the RNP assembly. The homology model of the
CDV nucleocapsid was created using the SWISS-Model homology-modeling server based on the
structure of the MeV Ncore assembly (PDB ID: 4UFT). B) Side-view of consecutive rungs of the
helical CDV RNP assembly. No structural information is available for the position of Ntail, but
box1 residues (yellow squares) are predicted to locate close to the outer surface of the RNP or

58

between consecutive turns of the RNP helix (shown in the model). The position of the A410D
substitution near the center of box1 is highlighted (red square).

The observations demonstrate that the NΔ441-479 truncation is genetically stable over a
number of generations in cell culture and after in vivo passage of the recombinant strain.
Efficient growth of recCDV-5804PeH NΔ425-479 appears to be linked to the presence of two
compensatory mutations, one located in Ncore (residue 156) and the second in box1 of Ntail
(residue 410). Localization of CDV N residue 156 in a structural model of the morbillivirus RNP
assembly posits this substitution at the C-terminal end of a flexible loop in Ncore (100),
orientated towards the interface between consecutive turns of the RNP helix (figure 18) and in
proximity to the site where Ntail is thought to emerge from the RNP core (88).

Supplemental Results
We wanted to determine the virus recovery of N-(Δ439-482) mutant virus in the MeVEdmonston (Edm) vaccine strain. MeV-Edm vaccine strain has been extensively used in our
laboratory. The truncations have been transferred to the MeV clinical isolate IC-B strain as
shown in the Appendix 1 – Thakkar et al (2018). The hypothesis was that the kinetics of Edm
mutant viruses would be different from the clinical isolate IC-B mutant viruses with the same
truncation.
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Figure 19: Recovery and expression analysis of recombinant Edmonston-MeV expressing N
mutant.
A-D) Multi-step growth curves of recMeV N(Δ439-482) cell-associated (A) or supernatant (B)
virus recovered at 37°C respectively, and recMeV N(Δ439-482) cell-associated (C) or
supernatant (D) virus recovered at 32°C respectively, as compared to the standard. Vero-hSLAM
cells were infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of
cell-associated/supernatent progeny virus at the indicated time points. Values represent means of
at least three independent experiments ± SEM. E, F) Expression levels of growth-curve cell
lysates of cell-associated virus strains recovered at 37°C (E) and at 32°C (F). Whole cell lysates
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of infected Vero-hSLAM were subjected to immunoblotting and detection with specific
antibodies directed against the MeV N protein.

To determine the importance of the unstructured Ntail section in virus replication in the
Edmonston strain, we substituted the N protein encoding ORFs in cDNA genome copies of
MeV-Edmonston vaccine strain with MeV NΔ439-482. As discussed earlier, RdRp activity in
minireplicon assays is not a necessary function to support viral replication cycle of that specific
mutant. Surprisingly, the corresponding recombinant mutant virus was recovered readily after
rescue transfection and overlay onto receptor-positive Vero-humanSLAM (Vero-hSLAM). DNA
sequencing after RT-PCR amplification of recovered virus genomes confirmed these viruses.
Multiple step growth curves were performed at 37°C and at 32°C (figure 19) with non-GFP
containing viruses.

These results demonstrate that the growth-kinetics at 37°C revealed an initial 12-hour growth
delay replication profile for recMeV-Edm- NΔ439-482 for the cell-associated and supernatant
recombinant viruses as compared with its standard. On the other hand, the peak titers for
recMeV-Edm- NΔ439-482 showed a 2-day delay profile at 32°C with respect to the cellassociated and supernatant viruses. This was replicated in the whole cell lysates of these viruses.
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A

B

C

Figure 20: Recovery of recombinant Edmonston-MeV (GFP) expressing N mutants.
A-C) Multi-step growth curves of recMeV-GFP N(Δ427-482) and recMeV-GFP N(Δ420-482)
cell-associated viruses recovered at 37°C (A), at 32°C (B) or at 39.5°C (C). Vero-hSLAM were
infected at an MOI of 0.01 TCID50 units/cell, followed by sampling and titration of cellassociated progeny virus at the indicated time points. Values represent means of at least three
independent experiments ± SEM.

Secondly, we substituted the N protein encoding ORFs in c-DNA genome copies of MeV-Edm
strain with MeV-GFP NΔ427-482 and with MeV-GFP NΔ420-482 respectively. MV
recombinants expressing the green fluorescent protein (GFP) have been used to monitor the
kinetics of the virus in the cell. We have therefore placed the GFP-ORF in the first ORF before
the N-protein ORF in order to observe them over a period of time. The corresponding
recombinant mutant viruses were recovered readily after rescue transfection and overlay onto
receptor-positive Vero-humanSLAM (Vero-hSLAM). DNA sequencing after RT-PCR
amplification of recovered virus genomes. Multiple step growth curves were performed at 37°C,
32°C and at 39.5°C (figure 20) with GFP containing viruses.
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These results demonstrate that the peak titers at 37° showed a 2 and 1.5-days delay
profile respectively, with respect to the standard C for recMeV-Edm-GFP NΔ427-482 and
recMeV-Edm-GFP NΔ420-482 respectively. The growth-kinetics of recMeV-Edm-GFP NΔ427482 and recMeV-Edm-GFP NΔ420-482 at 32°C showed a day-delay profile with half a log less
titer for the former than the latter. Additionally, at 39.5°C, recMeV-Edm-GFP NΔ427-482
mutant virus showed temperature-sensitivity, while recMeV-Edm-GFP NΔ420-482 mutant virus
peaked its titers a day later as compared to its corresponding standard.

This proves that the MeV replication is tolerant towards changes in both central Ntail
sequence and its length but there is more pronounced effect in the Edmonston strain than in the
clinical isolate IC-B strain. This also may be due to varying degrees of susceptibility of infection,
relative innate immune responses or also as discussed earlier difference in usage of receptors in
both the strains (the IC-B strain uses SLAM as a receptor, whereas the Edmonston strain can use
both SLAM and CD46 as receptors). Although, there is no correlation between the intrinsically
disordered central N-tail truncation and its specific viral fitness; further experiments are needed
to test these mutants in vivo, specifically in rhesus or cynomolgus macaques.

4

CONTINUED STUDIES

In order to probe the functional and mechanistic role of the central section of CDV-Ntail, we
have many questions that have still remain unanswered such as: 1) can we truncate further down
in the central CDV-N-tail section? 2) Can we truncate the CDV-N-tail section without an
artificial Afe-I site? 3) Is there a motif in the central section of the CDV-N-tail? If yes, is the
motif really important for viral replication? 4) Are the serine residues in the central section of
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CDV-N-tail phosphorylated? And are these residues important for virus rescue? Therefore, in
order to evaluate the functional role of the central section of the CDV N-tail further we continued
additional studies on the central section of the CDV N-tail.
Because of the minigenome data of CDV NΔ423 and CDV NΔ421 in the previous study,
we substituted the N protein encoding ORFs in cDNA genome copies of CDV strain CDV5804PeH. We also removed the artificial Afe-1 site and substituted the CDV NΔ425-479
plasmid mutant with alanine and aspartic acid residues to create: CDVNΔ425-SERS,
CDVNΔ425-SERA, CDVNΔ425-AERS, CDVNΔ425-AERA, CDVNΔ425-SERD, CDVNΔ425DERS, CDVNΔ425-DERD, respectively. The corresponding recombinant viruses were
recovered readily after rescue transfection and overlay onto receptor-positive Vero-canineSLAM
(Vero-cSLAM) cells. DNA sequencing after RT-PCR amplification of recovered virus genomes
confirmed CDV NΔ425-SERA and CDV NΔ425-DERD mutants but showed a mutation in box 1
of CDV NΔ425-SERS mutant recombinant virus (as shown in Table 2). This led us to believe
that the Afe-1 restriction site (SA) replaces the hypothesized natural phosphorylation site in the
central section of CDV-N-tail.
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Table 2: Summary of recCDV N mutant viruses
When we substituted N protein encoding ORF in cDNA genome copies of CDV strain
CDV-5804PeH (wild type (wt)), with the CDV N_AERA (CDV5804-N422-425Ala) and CDV
NΔ425-AERA, we could recover the former recombinant virus readily, but not the latter, after
rescue transfection and overlay onto receptor-positive Vero-canineSLAM (Vero-cSLAM) cells.
Finally, Vero-cSLAM cells were infected with CDV-5804PeH and CDV N_AERA at an MOI of
0.01 TCID50 units/cell, followed by sampling and titration of cell-associated progeny virus at the
indicated time points. The growth profiles overlapped as expected.

In the case of CDV N_AERA, we believe that the downstream serine residues would be
functional to regulate the phosphorylation activity we hypothesize in the central section of the
CDV N-tail. And in the case of CDV NΔ425-AERA, the hypothesized phosphorylation site is
important for CDV replication.
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5

DISCUSSION

Bioluminescent assays are very commonly used to study gene expression as well as other
cellular components and events that are involved in gene regulation. These assays are very
sensitive–allowing quantification of even small changes in transcription– and the availability of
results within minutes makes it appealing. They are extremely simple to use and relatively
inexpensive.

In bacteria, there is only one enzyme, however, eukaryotes have many polymerases that are
each responsible for a specific subset of RNAs. Various promoters are selected depending upon
whether viral transcription occurs in the nucleus or the cytoplasm during replication of the virus.
Although the majority of the RNA viruses replicate in the cytoplasm, the plasmids of this
protocol undergo nuclear transcription and the transcripts then undergo the downstream
processes in the cytoplasm. When human cells were cotransfected with different amounts of polI reporter plasmid and with optimized ratios of RSV helper plasmids (N, P, M2 – (0.4ug/well
each) and L (0.2ug/well). This was done in order to test the amount of reporter to be used
subsequently. The reporter was found to be active but the amount of reporter activity was not
directly proportional to the amount of reporter plasmid used at 50 hours post transfection as seen
in 28 hours post transfection. Although, the pol-I reporter assay showed some technical errors
and as the data was based on dependent replicates, the reporter was subsequently used in RSV
nucleoside analog testing successfully.

Since monocistronic minireplicons cannot address whether the viral transcriptase retains the
ability to successfully negotiate intergenic junctions, we employed a multicistronic reporter assay
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system. We first generated a novel firefly luciferase and gaussiluciferase containing bicistronic
minigenome constructs plasmids to address whether N-tail mutants allow RdRp to efficiently
negotiate the intergenic junctions in the viral genome. This kind of minigenome construct did not
show any appreciable signal and therefore we then generated firefly and nanoluciferase
containing bi- and tricistronic minigenome reporter.

In case of the bi and varied tricistronic constructs, the relative reporter expression levels of
MeV N-(Δ439-482) did not differ significantly as compared to the standard. In fact, the
bicistronic assay showed higher RdRp activity with the mutant as compared to the standard. In
the case of tri-P-stopstop construct, the relative reporter expression levels did not differ
significantly but was shown to be lower in case of mutant with respect to tri-eGFP and tri-(P(ΔCV). Since both- tri-eGFP and tri-(P-(ΔCV) are shorter than tri-P-stopstop, it seems to be
possible that the RdRp processivity depended on the extra residues missing. These results also
led us to believe that the non-structural proteins C and V do not influence the multicistronic
RdRp activity and show successful negotiation of intergenic junctions by the RdRp complex in
the absence of the unstructured Ntail section. Additionally, we have also employed such a
multicistronic (both bi- and tricistronic) reporter based system to determine RdRp activity in
different morbilliviral N-tail truncated constructs with increasingly large internal truncations of
central residues.

We have also generated a series of MeV, CDV, and NiV mutant N proteins with
increasingly large internal truncations of central Ntail residues, each ending immediately
upstream of MoRE near the Ntail C-terminus. Characterization of these constructs revealed the
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role of Ntail in RdRp bioactivity in biochemical assays and morbilliviral fitness and growth
kinetics in cell culture including CDV viral pathogenesis analysis. To probe an effect of Ntail
truncations on viral pathogenesis, recombinant CDVs were analyzed in a lethal CDV/ferret
model of morbillivirus disease. The recombinant viruses displayed different stages of attenuation
ranging from ameliorated clinical symptoms to complete survival of infected animals, depending
on the molecular nature of the Ntail truncation. Reinfection of surviving animals with pathogenic
CDV revealed robust protection against a lethal challenge. The highly attenuated virus was
genetically stable after ex vivo passaging and recovery from infected animals. Mechanistically,
gradual viral attenuation coincided with stepwise-altered viral transcriptase activity in infected
cells. These results identify the central Ntail section as a determinant for viral pathogenesis and
establish a novel platform to engineer gradual virus attenuation for next-generation
paramyxovirus vaccine design.
We can summarize our study using the following model:

Figure 21: Models of the mechanistic basis for the impact of Ntail on RdRp transcriptase
activity.
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(model kindly provided by J. Sourimant – from Institute for Biomedical Sciences, Georgia State
University)
Upon initialization at the terminal promoter, the viral P-L polymerase complex first synthesizes a
short Leader RNA (as shown in the figure 21: L is depicted in grey, P tetramers are shown in
blue, orange and yellow circles at the end of Ntails represent MoRE and box3, respectively).
Encapsidation of this Leader by N proteins switches the polymerase into replicase mode in which
it ignores intergenic junctions and generates a full-length encapsidated copy of the viral genome.
If not encapsidated, Leader is released by the polymerase complexes, which then travels in
transcriptase mode towards the first gene start site and proceeds generating viral mRNAs. In
either case, advancing of the RdRp along the genome involves the release of existing NMoRE/P-L interactions, Ntail reordering in front of the polymerase complex, and local deencapsidation of the viral RNA. A) In the first model, removal of the central Ntail section may
reduce the encapsidation efficiency of the nascent Leader RNA, causing a transcriptase bias of
the polymerase complex (thick horizontal arrow). B) Alternatively, elimination of the central
Ntail section may reduce the need for local Ntail ordering ahead of the advancing polymerase
complex, narrowing the time window available for Leader encapsidation by accelerating Leader
transcription (staggered horizontal arrows) promoting polymerase switch to transcriptase mode.

The significance of this study can be summarized as follows:
New Vaccination Strategy: The first attenuated live vaccine for MeV was developed by
adaptation of Edm strain to chick embryo fibroblasts but this vaccine was further passaged to
develop a more attenuated and non-reactogenic vaccine (137). Limitations to MeV vaccines do
exist including the potential for interference from maternal antibodies in young children
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preventing a strong protective response (138, 139). This has led to the re-emergence of MeV
infection in highly vaccinated populations (140).

Different individual point mutations have also been tested to engineer attenuation to
develop new vaccine strategies. But, this kind of strategy always has the risk of spontaneous
reversion to its pathogenic form. To overcome this, DNA vaccines have been proposed as an
alternative vaccination strategy for infants and in vivo studies recently. These have demonstrated
their potential utility (141, 142) as they elicit strong protective humoral and cell-mediated
immune response (143, 144). Although such vaccines are effective and relatively inexpensive to
produce, problems associated with vaccination regime and delivery routes need to be resolved.

With the help of an attenuation strategy, we can engineer the unstructured Ntail section in
order to modulate the varying degrees of attenuation to develop the next-generation vaccines.
This attenuation strategy by Ntail truncation may also be applicable to various other
paramyxovirus candidates as we have shown proof-of-concept in minireplicon systems for
highly pathogenic NiV. The main advantage of using an attenuation strategy for the development
of vaccines for closely related Paramyxoviruses is that it will be highly unlikely for the virus to
revert back and turn pathogenic as it cannot de novo synthesize the deleted residues of the
nucleoprotein. This kind of tunable attenuation can be very helpful for the development of an
efficient vaccines against highly pathogenic members of this family that do not have effective
prophylactic measures to date.
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Revising the current model of polymerase recruitment and progress along the template and
protein interactions: Our current understanding of Paramyxoviridae replication and how N, P
and L proteins interact is incomplete. It is also critically important to understand and revise the
current model of the proposed interactions between the proteins, in order to aid in the
development of effective antiviral treatments. In our study, N proteins with large tail truncations
remained bioactive in mono- and polycistronic minireplicon assays and supported efficient
replication of recombinant viruses. Bioactivity of Ntail mutants extended to N proteins derived
from highly pathogenic Nipah virus. We have hypothesized the predicted location of candidate
compensatory mutation to the NΔ425-479 truncation, thereby suggesting the cross-talk of N-core
and N-tail, in a model of the CDV RNP assembly. As shown in the figure 21, the truncation in
the central Ntail section may allow acceleration of the advancing polymerase complex. This may
reduce the time window available for encapsidation and may accelerate transcription.

Mechanistic role of the central section of the N-tail: Knowledge of the replication machinery
and the protein-protein interactions involved is very critical for the study and development of
effective prophylactic/therapeutic strategies. This study helped us to gain deeper insights into
their role in RdRp-mediated transcription and replication. Although the MeV N-tail is considered
dispensable for polymerase activity, it is considered to be important for stabilization of the P-L
complex onto RNP template (80) By making truncations in the central section of the N-tail, we
altered the molecular nature of the interface between N-terminal Ntail residues and the RNP
rungs. We noted two different degrees of viral attenuation, depending on the extent of the central
CDV-Ntail truncation. By analyzing the quantitations of viral RNA populations present in these
virus-infected cells, we observed a single versus double hit effect of the individual modifications
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in the N-tail on polymerase function. The first hit is termed by showing a partial shift of
polymerase activity from replicase to transcriptase mode compared to the parental recCDV
strain. This change was seen in cells infected with either CDV mutant virus. In addition to the
first hit, the recCDV NΔ441-479 recombinant also showed a second hit. The second hit shows a
relative higher proportion of polycistronic viral message, which directly affects the gradient of
functional viral mRNAs available in infected cells.

Currently, we cannot conclude whether these intrinsically disordered N-tails have developed
recently or whether they were present in the N proteins of an ancestral mononegavirales. As
there is an experimental confirmation that N-tail MORE can be readily moved into
paramyxovirus Ncore, we assume that ancestral nucleoproteins were tailless and then gradually
the N-tail developed in the modern viruses. As the N-tails developed, the nucleoproteins gained
novel N functions such as interactions with host cell factors, to fine-tune viral polymerase
activities, to regulate the natural paramyxovirus transcription gradient of mRNA synthesis. These
functions seem to explain the evolution of the unstructured Ntail region.

To summarize, we have confirmed that the truncations in the CDV central N-tail section are
possible. The additional CDV central N-tail truncated NΔ425 substitutions do not affect RdRp
activity. But, the central N-tail truncated mutant viruses closer to the RNP leads to accumulation
of some compensatory mutations. We are further investigating the role of a hypothesized motif
present in the central section of the CDV-N-tail that may regulate the viral activity. This will
give us a better understanding of the repeated serine residues (possibly a motif) present in the
central section of the N-tail and help us to definitely revise the current model of RdRp
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recruitment and progress along the template. The double-substituted aspartic-acid (CDVNΔ425_DERD) does not hamper virus rescue but CDV-NΔ425_SERS only grows further with
compensatory mutation in box 1 (so far seen). The negative charges/S421 phosphorylation at the
region near RNP in the N-tail seems to be important for viral replication. I hypothesize that the
421S residue is phosphorylated and this phosphorylated site between the box 1 and 2 and the
presence of all the conserved boxes are main factors important for efficient CDV replication.

The modeling of the cross-talk between morbilliviral N-tail residues and the N-core loop region
seems to be very interesting. Further experiments are needed to characterize the role of
compensatory mutations in central unstructured N-tail mutants closer to RNP in the future. The
effect of compensatory mutations in terms of minireplicon activity, viral fitness, viral
pathogenesis and transcription/replication balance needs to be further determined. In the future,
the influence of charges and/or S421 phosphorylation on the RNP surface needs to be identified.
It may be possible that this is applicable only to the interferon-negative Vero-dog SLAM cells
and that the actual hosts (carnivores) show different results. Further in-vivo experiments are
needed to prove this.
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